Intracerebral injection of CRISPR-LNPs against PLK1 into glioblastoma resulted in up to ~ 70% gene editing in vivo, leading to tumor cell apoptosis, a 50% reduction in tumor growth, and a 30% improvement in survival. Here, PLK1 is linked to neoplasm.